TIM-3 blockade on CD103+ CD141+ DC enhances the effect of chemotherapy in a mouse model of breast cancer by improving CD8+ T cell effector cell infiltration in the presence of CXCL9 upregulation on DC (90), demonstrating a DC associated mechanism of TIM-3 targeting in addition to its role in T cells. Here, HAVCR2 is linked to breast cancer.